Reverse Transcriptase Inhibitors

"Reverse Transcriptase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template.

Descriptor ID	D018894
MeSH Number(s)	D27.505.519.389.675.850 D27.505.954.122.388.077.750
Concept/Terms	Reverse Transcriptase Inhibitors Reverse Transcriptase Inhibitors Inhibitors, Reverse Transcriptase

Below are MeSH descriptors whose meaning is more general than "Reverse Transcriptase Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Nucleic Acid Synthesis Inhibitors [D27.505.519.389.675]
Reverse Transcriptase Inhibitors [D27.505.519.389.675.850]
Therapeutic Uses [D27.505.954]
Anti-Infective Agents [D27.505.954.122]
Antiviral Agents [D27.505.954.122.388]
Anti-Retroviral Agents [D27.505.954.122.388.077]
Reverse Transcriptase Inhibitors [D27.505.954.122.388.077.750]

Below are MeSH descriptors whose meaning is related to "Reverse Transcriptase Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Reverse Transcriptase Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Reverse Transcriptase Inhibitors" by people in this website by year, and whether "Reverse Transcriptase Inhibitors" was a major or minor topic of these publications.

Bar chart showing 26 publications over 17 distinct years, with a maximum of 4 publications in 2008

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	0	1
1998	0	1	1
1999	1	0	1
2000	1	1	2
2001	0	1	1
2002	1	1	2
2003	2	0	2
2005	1	1	2
2007	1	0	1
2008	3	1	4
2009	1	0	1
2010	1	1	2
2011	0	1	1
2014	0	1	1
2016	2	0	2
2019	0	1	1
2021	0	1	1

Below are the most recent publications written about "Reverse Transcriptase Inhibitors" by people in Profiles.

Eshleman SH, Fogel JM, Piwowar-Manning E, Chau G, Cummings V, Agyei Y, Richardson P, Sullivan P, Haines CD, Bushman LR, Petropoulos C, Persaud D, Kofron R, Hendrix CW, Anderson PL, Farrior J, Mellors J, Adeyeye A, Rinehart A, St Clair M, Ford S, Rooney JF, Mathew CA, Hunidzarira P, Spooner E, Mpendo J, Nair G, Cohen MS, Hughes JP, Hosseinipour M, Hanscom B, Delany-Moretlwe S, Marzinke MA. Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084. J Infect Dis. 2022 05 16; 225(10):1741-1749.

View in: PubMed
Engelman KD, Engelman AN. Long-Acting Cabotegravir for HIV/AIDS Prophylaxis. Biochemistry. 2021 06 08; 60(22):1731-1740.

View in: PubMed
Leporati A, Gupta S, Bolotin E, Castillo G, Alfaro J, Gottikh MB, Bogdanov AA. Antiretroviral Hydrophobic Core Graft-Copolymer Nanoparticles: The Effectiveness against Mutant HIV-1 Strains and in Vivo Distribution after Topical Application. Pharm Res. 2019 Mar 27; 36(5):73.

View in: PubMed
Leporati A, Novikov MS, Valuev-Elliston VT, Korolev SP, Khandazhinskaya AL, Kochetkov SN, Gupta S, Goding J, Bolotin E, Gottikh MB, Bogdanov AA. Hydrophobic-core PEGylated graft copolymer-stabilized nanoparticles composed of insoluble non-nucleoside reverse transcriptase inhibitors exhibit strong anti-HIV activity. Nanomedicine. 2016 11; 12(8):2405-2413.

View in: PubMed
Bolduc P, Roder N, Colgate E, Cheeseman SH. Care of Patients With HIV Infection: Antiretroviral Drug Regimens. FP Essent. 2016 Apr; 443:23-30.

View in: PubMed
Agosto LM, Zhong P, Munro J, Mothes W. Highly active antiretroviral therapies are effective against HIV-1 cell-to-cell transmission. PLoS Pathog. 2014 Feb; 10(2):e1003982.

View in: PubMed
Bavinger C, Bendavid E, Niehaus K, Olshen RA, Olkin I, Sundaram V, Wein N, Holodniy M, Hou N, Owens DK, Desai M. Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PLoS One. 2013; 8(3):e59551.

View in: PubMed
De Iaco A, Luban J. Inhibition of HIV-1 infection by TNPO3 depletion is determined by capsid and detectable after viral cDNA enters the nucleus. Retrovirology. 2011 Dec 06; 8:98.

View in: PubMed
Iarikov DE, Irizarry-Acosta M, Martorell C, Hoffman RP, Skiest DJ. Low prevalence of primary HIV resistance in western Massachusetts. J Int Assoc Physicians AIDS Care (Chic). 2010 Jul-Aug; 9(4):227-31.

View in: PubMed
McKinnell JA, Willig JH, Westfall AO, Nevin C, Allison JJ, Raper JL, Mugavero MJ, Saag MS. Antiretroviral prescribing patterns in treatment-na?ve patients in the United States. AIDS Patient Care STDS. 2010 Feb; 24(2):79-85.

View in: PubMed

People

Explore

Similar Concepts

Top Journals